BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 9552023)

  • 1. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
    Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
    J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
    J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
    Nickerson HJ; Matthay KK; Seeger RC; Brodeur GM; Shimada H; Perez C; Atkinson JB; Selch M; Gerbing RB; Stram DO; Lukens J
    J Clin Oncol; 2000 Feb; 18(3):477-86. PubMed ID: 10653863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
    London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
    J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
    Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
    J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
    Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
    J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
    West DC; Shamberger RC; Macklis RM; Kozakewich HP; Wayne AS; Kreissman SG; Korf BR; Lavally B; Grier HE
    J Clin Oncol; 1993 Jan; 11(1):84-90. PubMed ID: 8418247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
    Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
    Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
    Matthay KK; O'Leary MC; Ramsay NK; Villablanca J; Reynolds CP; Atkinson JB; Haase GM; Stram DO; Seeger RC
    Eur J Cancer; 1995; 31A(4):572-5. PubMed ID: 7576971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
    Seeger RC; Reynolds CP; Gallego R; Stram DO; Gerbing RB; Matthay KK
    J Clin Oncol; 2000 Dec; 18(24):4067-76. PubMed ID: 11118468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review.
    Kushner BH; Cheung NK; LaQuaglia MP; Ambros PF; Ambros IM; Bonilla MA; Ladanyi M; Gerald WL
    J Clin Oncol; 1996 Jul; 14(7):2174-80. PubMed ID: 8683252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
    Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
    J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
    Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
    J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.
    Umehara S; Nakagawa A; Matthay KK; Lukens JN; Seeger RC; Stram DO; Gerbing RB; Shimada H
    Cancer; 2000 Sep; 89(5):1150-61. PubMed ID: 10964346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.